Clene (CLNN) logo

Clene (CLNN) stock

Market cap $49.3MShares as of Aug 11

$3.84
-1.03%

As of Monday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score CLNN. It is too thinly traded for a fair Quality Score.

Healthcare · Pharma

NextQ4 2026“…Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026”Filing with regulators · SEC filing · Aug 14
Cash$9.7M, about 2 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “through mid-first quarter 2027”

Follow CLNN's news. Pro members can get an alert when Clene files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CLNN files newsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,191 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$9.7M, about 2 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “through mid-first quarter 2027”

What's next for CLNN, and how long its cash lasts

Next step the company has named

Q4 2026“Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026”Filing with regulators · SEC filing · Aug 14

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

For Pro members: 58 filings.

Cash runway Jun 30 balance sheet

About 2 quarters

$9.7M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “through mid-first quarter 2027” (8-K, Sep 16). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Mar 24, 2025)
  • At-the-market share sales program (424B5, filed Apr 28, 2025)

For Pro members: 8 raises and their amounts, and the share count against a year ago.

Insiders

Director David J Matlin bought 33,333 shares on Jan 13.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Robert Etherington’s 18 filings and quotes.

Get an alert when CLNN files newsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

CLNN's latest filings

53 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why CLNN isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. CLNN trades about 99,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

The price on this page is delayed at least 15 minutes.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.